The DOI matches its Crossref record.
Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma
Abstract
A high-performance liquid chromatographic (HPLC) method with fluorescence detection was developed and validated for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. Sarafloxacin was used as internal standard. Chromatography was carried out using a Waters XBridge C(18) HPLC column and a gradient mobile phase consisting of CH(3)CN/MeOH/0.025M TBA.Cl/TFA (eluent A at 75/25/899/1 (v/v); eluent B at 150/50/799/1 (v/v); both at pH 3.5). Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard. Prior to chromatography, plasma samples were treated with acetonitrile for protein precipitation, followed by evaporation of the liquid layer and reconstitution in eluent A. The method was validated for the three fluoroquinolones over the clinically relevant concentration range from 0.02 to 7.50mug/ml. The method showed acceptable linearity with correlation coefficients, r(2)>0.995, as well as high precision (RSD% <7% in each case), accuracy (90.4-105.4%) and selectivity. The limit of quantification for the three fluoroquinolones was established at 0.02mug/ml. Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively. During validation, the concentration of the three fluoroquinolones was found to be stable after 3 freeze-thaw cycles and for at least 15h after extraction. This bio-analytical method was finally…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These reported HPLC assays have extensive chromatographic run times.
“These assays have some disadvantages in terms of extensive chromatographic run times [9,11-13,15,16] a large consumption of non environmentally friendly solvents [11] or a large amount of sample [11,15,16].”
Several HPLC assays with ultraviolet detection for the determination of these drugs, alone or in combination, have been reported.
“Several HPLC assays with ultraviolet (UV) detection for the determination of these drugs, alone or in combination, have been reported [9-17].”
These reported HPLC assays require a large amount of sample.
“These assays have some disadvantages in terms of extensive chromatographic run times [9,11-13,15,16] a large consumption of non environmentally friendly solvents [11] or a large amount of sample [11,15,16].”
These reported HPLC assays consume large amounts of non environmentally friendly solvents.
“These assays have some disadvantages in terms of extensive chromatographic run times [9,11-13,15,16] a large consumption of non environmentally friendly solvents [11] or a large amount of sample [11,15,16].”
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 24
- Viale, 2003, J. Chemother., 15, 5, 10.1179/joc.2003.15.Supplement-2.5 · DOI
- Peyrani, 2008, Infect. Med., 25, 161
- Moran, 2006, Emerg. Med., 30, 377, 10.1016/j.jemermed.2005.07.009 · DOI
- Boucher, 2006, Crit. Care Clin., 22, 255, 10.1016/j.ccc.2006.02.011 · DOI
- Zagli, 2008, Fund. Clin. Pharmacol., 22, 493, 10.1111/j.1472-8206.2008.00623.x · DOI
- Soy, 2006, Curr. Opin. Crit. Care, 12, 477, 10.1097/01.ccx.0000244130.77365.c2 · DOI
- Laban-Djurdjevic, 2006, J. Chromatogr. B, 844, 104, 10.1016/j.jchromb.2006.07.001 · DOI
- Takacsnovak, 1995, J. Liquid Chromatogr., 18, 807, 10.1080/10826079508009274 · DOI
- Garcia, 1999, Biomed. Chromatogr., 13, 350, 10.1002/(SICI)1099-0801(199908)13:5<350::AID-BMC889>3.0.CO;2-C · DOI
- Idowu, 2004, J. Pharm. Biomed. Anal., 35, 143, 10.1016/j.jpba.2004.01.006 · DOI
- Sowinski, 2004, J. Clin. Pharm. Ther., 29, 381, 10.1111/j.1365-2710.2004.00575.x · DOI
- Imre, 2003, J. Pharm. Biomed. Anal., 33, 125, 10.1016/S0731-7085(03)00151-1 · DOI
- Zotou, 2002, J. Pharm. Biomed. Anal., 28, 559, 10.1016/S0731-7085(01)00689-6 · DOI
- Maya, 2001, J. Chromatogr. B, 755, 320, 10.1016/S0378-4347(01)00126-8 · DOI
- Ulu, 2007, J. Pharm. Biomed. Anal., 43, 320, 10.1016/j.jpba.2006.11.005 · DOI
- Lemoine, 2000, J. Chromatogr. B, 742, 247, 10.1016/S0378-4347(00)00166-3 · DOI
- Garcia, 2002, Chromatographia, 55, 431, 10.1007/BF02492272 · DOI
- Immanuel, 2001, J. Chromatogr. B, 760, 91, 10.1016/S0378-4347(01)00260-2 · DOI
- Macek, 1995, J. Chromatogr. B, 673, 316, 10.1016/0378-4347(95)00263-5 · DOI
- Samanidou, 2003, Anal. Bioanal. Chem., 375, 623, 10.1007/s00216-003-1749-9 · DOI
- Chan, 2006, Anal. Biochem., 353, 30, 10.1016/j.ab.2006.03.016 · DOI
- Liang, 2002, J. Chromatogr. B, 772, 53, 10.1016/S1570-0232(02)00046-6 · DOI
- Long, 1983, Anal. Chem., 55, 712A, 10.1021/ac00258a001 · DOI
- Montay, 1985, J. Chromatogr., 339, 214, 10.1016/S0378-4347(00)84647-2 · DOI
Cited by
Sorted by citations
Ferrone, V., Cotellese, R., Carlucci, M., Di Marco, L., & Carlucci, G. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.039 · Cited by 43
Metadata
- Authors
- De Smet, J., Boussery, K., Colpaert, K., De Sutter, P., De Paepe, P., Decruyenaere, J., & Van Bocxlaer, J.
- Affiliations
- Ghent University (BE)
- Ghent University Hospital (BE)
- Venue
- Journal of Chromatography B
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 877
- Issue
- 10
- Pages
- 961-967
- ISSN
- 1570-0232 (ISSN-L)
- OpenAlex
- W1980041883
- Cited by
- 71
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 7 · 2012: 7
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chromatography B (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- fluoroquinolones, ofloxacin, ciprofloxacin, moxifloxacin, pharmacokinetics, critically ill patients, simultaneous determination, human plasma, fluorescence detection, HPLC method validation
- MeSH terms
- Moxifloxacin, Aza Compounds, Chromatography, High Pressure Liquid, Ciprofloxacin, Humans, Quinolines, Ofloxacin, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
